Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 AUD | -25.00% | -.--% | -14.29% |
May. 16 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Sales 2022 | 1.13M 751K | Sales 2023 | 474K 315K | Capitalization | 11.09M 7.38M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.33M | Net income 2023 | -3M -2M | EV / Sales 2022 | 23.3 x |
Net cash position 2022 | 1.22M 813K | Net cash position 2023 | 5.33M 3.55M | EV / Sales 2023 | 12.2 x |
P/E ratio 2022 |
-11.5
x | P/E ratio 2023 |
-2.31
x | Employees | 15 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.6% |
1 day | -25.00% | ||
1 month | -25.00% | ||
Current year | -14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Paul David Gavin
CEO | Chief Executive Officer | - | 01-12-31 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 18-12-27 |
Roksan Libinaki
COO | Chief Operating Officer | - | 00-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ross Murdoch
BRD | Director/Board Member | - | 15-01-13 |
Director/Board Member | 60 | 20-01-12 | |
Gregory Collier
CHM | Chairman | - | 15-04-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.003 | -25.00% | 479,690 |
24-05-30 | 0.004 | +33.33% | 121,429 |
24-05-29 | 0.003 | -25.00% | 390,836 |
24-05-28 | 0.004 | +33.33% | 472,909 |
24-05-27 | 0.003 | -.--% | 1,804 |
Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-14.29% | 6.31M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- AVE Stock